Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

1819133

We are leveraging the principle of synthetic lethality to develop medicines that take direct aim at specific tumors. Using an approach that starts and ends with patients, we’re expanding the reach of genetically targeted therapies.

84
Très Fiable
Score de Confiance

Registre Officiel

Dénomination Sociale
Tango Therapeutics, Inc.
Numéro d'organisation
1819133
Statut de l'Entreprise
Active

Analyse Qualité IA

Industrie
Biopharmaceutical
SSL/HTTPS
Sécurisé
E-mail professionnel
Oui
E-mail de contact
bd@tangotx.com

Détails du Score de Confiance

Registre Vérifié35/35
Score de Qualité49/60
Sentiment de l'Actualité0/5

Liens Rapides

Dernière mise à jour: 12/29/2025

🌟 Entreprises similaires de confiance

BRISTOL MYERS SQUIBB CO

BRISTOL MYERS SQUIBB CO logo
75/100 · Fiable

Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines. Their key products and services include treatments for cancer, cardiovascular disease, immunology, and other serious diseases. BMS is positioned as a leading company in the pharmaceutical industry, with a commitment to research and development to improve patient outcomes.

États-Unis
Voir le profil

Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. logo
72/100 · Fiable

Aldeyra Therapeutics is dedicated to developing medications for immune-mediated diseases. They target the inhibition of inflammatory cells associated with ocular and systemic ailments. Their focus is on developing next-generation medicines for unmet needs. They have investigational therapies in late-stage clinical testing.

États-Unis
Voir le profil

TG THERAPEUTICS, INC.

TG THERAPEUTICS, INC. logo
71/100 · Fiable

TG Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Their lead product, BRIUMVI® (ublituximab-xiiy), is approved for the treatment of relapsing forms of multiple sclerosis (MS). The company is dedicated to research and development within these therapeutic areas.

États-Unis
Voir le profil